Researchers at the Icahn School of Medicine at Mount Sinai have demonstrated that the recently developed antidiabetic drug empagliflozin can treat and reverse the progression of heart failure in non-diabetic animal models. Their study also shows that this drug can make the heart produce more energy and function more efficiently. The results were published in the April 23 issue of the Journal of the American College of Cardiology.

Biotronik announced the European market release of what it calls the world’s smallest implantable cardioverter defibrillator (ICD) and cardiac resynchronization therapy defibrillator (CRT-D) devices that are approved for 3T full-body magnetic resonance imaging (MRI) scans.

DiA Imaging Analysis has partnered with the Italian healthcare IT company Ebit (Esaote Group), to offer DiA’s LVivo Cardiac Toolbox as an integrated part of Ebit's Suitestensa CVIS (cardiovascular information system). The LVivo Cardiac Toolbox is designed to analyze cardiac ultrasound images based on more objective and reproducible information, as opposed to manual measurement or visual analysis methods that are currently being used.

CardioFocus Inc. announced the European CE Mark approval of the HeartLight X3 Endoscopic Ablation System.

For the first time in the United States, doctors with the American Heart Association (AHA) have outlined best practices for cardiologists to evaluate and manage patients who have heart attacks with no significant signs of coronary artery disease — a condition known as myocardial infarction with non-obstructive coronary arteries (MINOCA). The new document, published in the March 27 issue of Circulation,1 aims to help physicians better recognize patients with this condition, to avoid common misdiagnoses and streamline care. It is especially important for women, who represent a disproportionate number of MINOCA cases.